2019 ANNUAL REPORT. Download the AstraZeneca Annual Report and Form 20-F Information 2015. Crestor achieved sales of $2,844 million (2014: $2,918 million; 2013: $2,912 million) and a total prescription share within the statin market of 8.9% in December 2015. 8 AstraZeneca Annual Report 2016-17 NOTICE NOTICE is hereby given that the 38th Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held on Wednesday, September 13, 2017 at 3.00 p.m. at ‘The Mysore Hall’, ITC Gardenia, No.1, Residency Road, Bangalore – 560025, to transact the following business: ORDINARY BUSINESS Annual Financial Report Tue, Mar 03, 2020 12:00 CET. We have a strong global commercial presence, with strength in Emerging Markets. Over the past decade, we have supported our organic growth programs and prioritized business needs while also investing * WHO data AstraZeneca is one of only a handful of pure-play biopharmaceutical Strategic overview In 2018, we achieved a significant milestone by returning to Product Sales growth. Download our full Annual Report and Form 20-F Information 2015, Notice of AGM 2016 and Shareholders' Circular. AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2015 (Annual Report). D. Selling Shareholders . In 2019, we refreshed our strategy to focus on what comes next, and where we want our business to be in 2025. Find out the revenue, expenses and profit or loss over the last fiscal year. AstraZeneca Annual Report and Form 20-F Information 2013 1 Additional Information Financial Statements Corporate Governance. Annual Revenue ( $ ) AstraZeneca revenue was $24.38 b in FY, 2019 which is a (10.4%) year over year increase from the previous period. Key Achievements 1 AstraZeneca Annual Report and Form 20-F 2000 Key Achievements Sales* of $15.8 billion, up 8% Operating profit* of $4.0 billion, up 14% US pharmaceutical sales of $8.0 billion, up 12% Losec sales of $6.3 billion, up 9% Sales of seven products each exceed $500 million – Losec, Zestril, Seloken, Zoladex, Pulmicort, Diprivan & Nolvadex In the US, Crestor sales declined 57% to $1,223 million, reflecting entry of generic Crestor. Download the AstraZeneca Annual Report and Form 20-F Information 2015. This website is intended for people seeking information on AstraZeneca's worldwide business. 2015 was an exceptional year for AstraZeneca, as we made significant progress in meeting both our near- … This database is a … Report on Corporate Governance – 31 Dec 2020. Established in 1993, the AstraZeneca HealthCare Foundation is a Delaware not-for-profit corporation and a 501(c)(3) entity organized for charitable purposes, including to … Please refer to your approved national product label (SmPC) for current product information. 10,000+ Employees. We have distinctive R&D capabilities in small molecules, biologics, immunotherapies, protein engineering and devices. PDF 1,145KB Annual Report 2014-15. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. $775K awarded in grants 18K+ people reached 5,500+ participants AstraZeneca is a global, science-led biopharmaceutical business with an on-market portfolio in our chosen therapy areas. Annual Financial Report. 9 AstraZeneca Annual Report 2015-16 AstraZeneca Pharma India Limited Board of Directors Committees of Directors Mr. D. E. Udwadia, Chairman Mr. K. S. Shah Mr. Narayan K Seshadri Mr. lan Brimicombe Mr. Sanjay Murdeshwar, Managing Director Ms. Claire-Marie O'Grady (from November 6, 2015) Mr. Justin Ooi (upto January 11, 2016) Product Sales (2014: $10,710m, 2013: $10,328m), Product Sales (2014: $6,638m, 2013: $6,658m), Product Sales (2014: $8,747m, 2013: $8,725m). The Board of Directors has sought to ensure that AstraZeneca's achievements in 2015 were underpinned by strong corporate governance. Financial statements and reports for AstraZeneca plc (AZN) Ordinary US$0.25 including annual reports and financial results for the last 5 years. AstraZeneca at a glance We are a global, innovation-driven biopharmaceutical business. We encourage you to read the privacy policy of every website you visit. You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents. Established in 1993, the AstraZeneca HealthCare Foundation is a Delaware not-for-profit corporation and a 501(c)(3) entity organized ... 2009 2015 2013 2019 2010 2016 2014 2011 2017 2012 2018 $25M. PDF 10,487KB Watch this year in review. 2015 Annual Report; PDF ; 2014 Annual Report; PDF ; 2013 Annual Report; PDF ; 2012 Annual Report ... About AstraZeneca plc. Annual Report 2015-16. Get a detailed Sensex annual report of AstraZeneca Pharma on stock/share exchange market for the financial 2015 and more at Moneycontrol.com AstraZeneca is not responsible for the privacy policy of any third party websites. PDF 4,284KB ... You are now leaving AstraZeneca.in. ANNUAL REPORT INSPIRING ACTION TO HELP IMPROVE HEART HEALTH IN COMMUNITIES ACROSS THE U.S. Based in Cambridge, England. Important notice for users AstraZeneca Annual Report and Form 20-F Information 2016 Welcome to the AstraZeneca Annual Report and Form 20-F Information 2016.. We encourage you to read the privacy policy of every website you visit. Respiratory. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements (S-1, S-8) and prospectus (FWP). Visit website. This website is intended for people seeking information on AstraZeneca's worldwide business. publications: our annual report, covering our business and fi nancial results, and our corporate responsibility report, focused on our broad-based social and environmental goals, activities, and impacts. PDF 4,810KB Annual Report 2013 - Swedish. PDF 4,031KB 2012. The Annual Report is also available on the Company's website at http://www.astrazeneca-annualreports.com/2015/. In 2015, AstraZeneca completed the acquisition of ZS Pharma. PDF 4,097KB AstraZeneca PLC Long Term Incentive Plans for Executive Directors. I have read this warning and will not be using any of the contained product information for clinical purposes. Our country sites can be located in the AZ Network. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. AstraZeneca Annual Report and Form 20-F Information 2015. Cooperation project. PDF 555KB 10,487KB 2014. AstraZeneca Annual Report and Form 20-F Information 2015, Respiratory sales up by 7%, including 25% in Emerging Markets, before completion of the acquisition of Takeda's respiratory business, Diabetes sales up by 26%, including 76% in Emerging Markets, New Oncology included for the first time (comprising, Sales in the US declined by 6% reflecting entry of generic, Favourable performances were delivered by, Strong growth for Diabetes medicines was offset by generic competition facing, Emerging Markets revenue grew by 12% to $5,822 million, including China sales growth of 15%, Sales in Japan grew by 4% to $2,020 million, Identify unmet medical need aligned with our three therapy areas and undertake scientific research to identify potential new medicines, Initiate process of seeking patent protection, Conduct laboratory and animal studies to understand if the potential medicine is safe to introduce into humans and in what quantities, Determine likely efficacy, side effect profile and maximum dose estimates, Begin clinical studies with small groups of healthy human volunteers (small molecules) or patients (biologics) to understand how the potential medicine is absorbed into the body, distributed around it and excreted, Determine approximate dosage and identify side effects, Conduct studies on small- to medium-sized groups of patients to test effectiveness and tolerability of the medicine and determine optimal dose, Design Phase III studies to generate data needed for regulatory approvals and pricing/reimbursement globally, Engage in studies in a larger group of patients to gather information about effectiveness and safety of the medicine and evaluate the overall benefit/risk profile, Initiate branding for the new medicine in preparation for its launch, Seek regulatory approvals for manufacturing, marketing and selling the medicine, Submit clinical data to regulatory authorities (and, if requested, generate further data increasingly in real-world settings) to demonstrate the safety and efficacy of the medicine to enable them to decide on whether to grant regulatory approvals, Raise awareness of patient benefit and appropriate use, market and sell medicine, Clinicians begin to prescribe medicines and patients begin to benefit, Continuously monitor, record and analyse reported side effects. Get the detailed quarterly/annual income statement for Astrazeneca PLC (AZN). This Annual Report quick-read provides top-level information on our business and the progress we have made in 2017 in pushing the boundaries of science to deliver life-changing medicines. Not applicable. AstraZeneca Pharma share price jumps 11% on WHO approval for emergency use of COVID-19 vaccines 08.02.2021 AstraZeneca Standalone December 2020 Net Sales at Rs 200.25 crore, down 10.55% Y-o-Y It is a listed company and is a subsidiary of AstraZeneca Plc, UK. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Our country sites can be located in the AZ Network. Increasing our proximity to bioscience clusters and co-locating around three strategic R&D centres. Please refer to your approved national product label (SmPC) for current product information. Important notice for users I have read this warning and will not be using any of the contained product information for clinical purposes. Research and Development phases 10-15 years. PDF 11,262KB 01. In 2009, the AstraZeneca HealthCare Foundation launched the Connections for Cardiovascular HealthSM (CCH) program with a $25 million contribution from AstraZeneca Pharmaceuticals. AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2019 (the Annual Report). AstraZeneca revenue increased from $22.1 billion in 2018 to $24.4 billion in 2019, a (10.4%) increase. 2020. ... on page 229 of AstraZeneca’s “Annual Report and Form 20-F Information 2017” included as exhibit 15.1 to this Form 20- F dated March 6, 2018 is incorporated by reference. The program awards annual grants to nonprofit organizations working to improve cardiovascular health at the community level. Our talented employees are committed to achieveing our Purpose in a sustainable way. astrazeneca-annualreports.com 内容説明：Annual Report and Form 20-F Information 2014 Published 10 March 2015 Our Annual Report provides a wide range of … ... 2017 represented a defining year for AstraZeneca. Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. Review need to update the side effect warnings to ensure that patients’ wellbeing is maintained, Assess real-world effectiveness, and opportunities to support patients and prescribers, to achieve maximum benefit from the medicine, Conduct studies to further understand the benefit/risk profile of the medicine in larger and/or additional patient populations, Life-cycle management activities to broaden understanding of a medicine’s full potential, Consider additional diseases or aspects of disease to be treated by or better ways of administering the medicine, Submit data packages with requests for life-cycle management to regulatory authorities for review and approval. The Annual Report is also available on the Company’s website at: www. All employee numbers are approximate as at 31 December 2015. Annual Report 2012 - English. CVMD sales represented 38% of Total Product Sales. The Annual Report … You are about to access AstraZeneca historic archive material. 2015 was an exceptional year for AstraZeneca, as we made significant progress in meeting both our near- and longer-term strategic goals. AstraZeneca is not responsible for the privacy policy of any third party websites. Sales of Onglyza in the US declined 10% to $376 million, as we prioritised Farxiga. Our fi rst integrated report, covering our performance in 2015… 2 GSK Annual Report 2015 Strategic report Governance & remuneration Financial statements Investor information Our investor proposition GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products. Our disciplined capital allocation enables commitment to a progressive dividend. 3 March 2020 11:00 GMT . Product Sales (2014: $5,063m, 2013: $4,677m), Product Sales (2014: $9,802m, 2013: $8,830m), Product Sales (2014: $3,027m, 2013: $3,193m), Product Sales (2014: $8,203m, 2013: $9,011m). Veeva ID: Z4-25396Date of next review: August 2022. AstraZeneca Pharma India Limited (AZPIL) is the operating company and covers manufacturing, sales and marketing activities of the company in India. AstraZeneca Annual Report 2014-15 3 NOTICE NOTICE is hereby given that the 36th Annual General Meeting of the Members of AstraZeneca Pharma India Limited will be held on Wednesday, September 2, 2015 at 11.00 a.m. at Vivanta by Taj Hotel, MG Road, Bangalore 560001, to transact the following business: ORDINARY BUSINESS 1. What science can do. During 2015, we increased our dividend for the 53rd consecutive year, we invested nearly $2.5 billion in licensing, acquisitions and strategic partnerships, and we announced a $10 billion share repurchase program in October. Astrazeneca Plc (AZN) SEC Filing 20-F Annual report for the fiscal year ending Thursday, December 31, 2020 AstraZeneca Annual Report and Form 20-F Information 2015 pill in the US and more than a million new patients started therapy on Crestor in 2015. Product Sales (2015: $9,489m, 2014: $9,802m) Highlights. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. PDF 102KB 2013. A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. PDF 288KB Corporate Governance. Annual Report and Form 20-F Information 2019 Download the full Annual Report. Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed. AstraZeneca Report year: 2015 Location: UK Industry: Health Care Report type: Annual Report Online report approach: Hybrid HTML Report link (english): AstraZeneca - Annual Report and Form 20-F Information 2015. astrazeneca.com/annualreport2019. AstraZeneca provides this link as a service to website visitors. Learn about our main therapy areas: We are a global, science-led biopharmaceutical business and in this Annual Report we report on the progress we made in 2016 in Oncology pushing the boundaries of science Our ambition is to eliminate cancer … Get a detailed Sensex annual report of AstraZeneca Pharma on stock/share exchange market for the financial 2018 and more at Moneycontrol.com A copy of the Annual Report will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. Annual Report 2014 - English. You are about to access AstraZeneca historic archive material. AstraZeneca provides this link as a service to website visitors. Annual Report 2015 - English. PDF 5,660KB Annual Report 2014 - Swedish. Veeva ID: Z4-25396Date of next review: August 2022. AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2019 (the Annual Report). Annual Report 2013 - English. Limited Review Report 2015-2016 Q1. AstraZeneca PLC Long Term Incentive Plans for Executive Directors.